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In complex multisymptom disorders like ﬁbromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS) that are deﬁned
primarily by subjective symptoms, genetic and gene expression proﬁles can provide very useful objective information. This paper
summarizes research on genes that may be linked to increased susceptibility in developing and maintaining these disorders,
and research on resting and stressor-evoked changes in leukocyte gene expression, highlighting physiological pathways linked
to stress and distress. These include the adrenergic nervous system, the hypothalamic-pituitary-adrenal axis and serotonergic
pathways,andexerciseresponsivemetabolite-detectingionchannels.Theﬁndingstodateprovidesomesupportforbothinherited
susceptibility and/or physiological dysregulation in all three systems, particularly for catechol-O-methyl transferase (COMT)
genes, the glucocorticoid and the related mineralocorticoid receptors (NR3C1, NR3C2), and the purinergic 2X4 (P2X4) ion
channel involved as a sensory receptor for muscle pain and fatigue and also in upregulation of spinal microglia in chronic
pain models. Methodological concerns for future research, including potential inﬂuences of comorbid clinical depression and
antidepressants and other medications, on gene expression are also addressed.
1.Introduction
The concept that ﬁbromyalgia syndrome (FMS) may involve
inherited susceptibility is not new, nor is the related hypoth-
esis that FMS pathogenesis involves a genetic susceptibility
combined with environmental exposure that triggers further
changes in expression of the same gene(s) or other interact-
ing genes [1–3]. These environmental events might include
one or several of the following: traumatic injury, bacterial or
viral infection, surgery, or chronic intermittent life stressors.
All of these environmental events increase stress exposure
(deﬁned as the external events themselves) and distress
(deﬁned by the individual’s physiological and emotional
responses to stressful events). Increased distress is also a
consequence of the chronic pain of FMS itself and its cost to
normal work, family, and social functioning [4, 5]. This
distress may be greater in those individuals with speciﬁc
biological predispositions that alter function of the two
main stress pathways, the sympathetic (adrenergic) and
hypothalamic-pituitary-adrenal (HPA) axes [6]. Distress is
certainly greater in those with psychobiological predisposi-
tions, such as depression, anxiety, and pain catastrophizing,
all of which are intercorrelated with each other and with
severity of disability [7] .T h ef o c u so ft h i sr e p o r ti so nt h e
geneticfactorsthatmayunderliethesesusceptibilities(inher-
ited DNA) and on the gene-environment interactions that
can lead to altered gene expression (mRNA) and thereby
change the neural and immune pathways that regulate the
primary symptoms of muscle pain and fatigue.
In order to rigorously test for possible genetic and gene
expression contributions in FMS, it is vital that within the
broadly inclusive FMS patient deﬁnition, key patient sub-
groups must be carefully deﬁned to be as homogeneous as
possible. Diagnosis of FMS is currently undergoing some2 Pain Research and Treatment
evolution, but is based largely on subjective reports of
widespread pain involving muscles and joints that last for 3
months or longer. Research on genes and gene expression in
FMS may identify objective biomarkers for the disorder, as
well as indicate pathways that are dysregulated and thus are
potential targets for therapeutic intervention. Many patients
meetingtheolderAmericanCollegeofRheumatology(ACR)
criteria for FMS, which requires widespread hyperalgesic
response to Tender Point testing [8], also meet the Fukuda et
al. and Reeves et al. [9] criteria for chronic fatigue syndrome
(CFS); this percentage has been reported from 21–80%, with
less overlap in primary care and population studies but
approaching 70% in specialized referral clinics [10]. It has
even been suggested that FMS, CFS, and other overlapping
somatic disorders like irritable bowel syndrome (IBS), and
other noncardiac chronic pain conditions should be classi-
ﬁed as a single disorder labeled “bodily distress syndrome”
[11]. The more recent recommendations for clinically deﬁn-
ing FMS without requiring Tender Point testing and high-
lighting fatigue as one of the central constellation of symp-
toms [8, 12, 13] is likely to further increase the overlap of
CFS and FMS. With the broader deﬁnition of FMS, however,
there is also a greater likelihood of inclusion of subgroups
with diﬀering etiologies involving disparate genetic and gene
expression proﬁles. Because of the overlap in these syn-
dromes, in the present report, we will summarize the litera-
tureongeneticallelicdiﬀerencesandgeneexpressioninboth
FMS and CFS, with an emphasis on stress-related genes that
may indicate dysregulation in three interacting neural path-
ways: the adrenergic nervous system known to be activated
during many types of physical and mental stress, the sero-
tonin and HPA axis linked to distress through depression,
and the purinergic and other ion channel receptors (e.g.,
acid sensing ion channel (ASIC) and transient vanilloid-1 or
capsaicin receptors (TRPV1)) that our own research linked
to increased pain and fatigue symptoms in patients with CFS
and comorbid FMS following moderate physical activity.
Table 1 lists the various stress-related genes addressed in this
review.
2. FunctionalImportance of Adrenergic
andIon ChannelReceptorsinthePainand
Fatigueof FMS andCFS
Adrenergic receptors are best known for their function
as components of the eﬀerent sympathetic pathway, with
greatest emphasis on the heart and vasculature as the target
organs. A change in central sympathetic activity initiates an
increase or decrease in neural activity to β-1 receptors in
the myocardium altering heart rate and contractile force,
and to α receptors in arterial and venous vessels, inﬂuencing
constriction and dilation and thereby altering blood ﬂow
to speciﬁc tissues and venous return to the heart. Equally
important in the regulation of blood ﬂow are the vascular
β-2 receptors which enhance dilation when activated, a
response that principally occurs in response to increased
circulating levels of norepinephrine and epinephrine. The
levels of these circulating amines reﬂect the sum of both
adrenal production and local release from postganglionic
sympathetic nerve ﬁbers, but may also reﬂect the rate of
metabolism which varies as a function of key enzymes,
particularlycatechol-O-methyltransferase(COMT).Whatis
less commonly noted is that vascular β-2 receptors are also
critical components of the metabolic pathway that causes
bloodﬂowtoincreaseinaspeciﬁcmusclewhenthatmuscle’s
activity increases and more metabolites of activity are
produced (local autoregulation). Because this local autoreg-
ulation is so ﬁrmly tied to increases and decreases in local
metabolic activity, this necessarily involves communication
between the vascular β-2 receptors and the sensory ion
channelreceptorsthatareinvolvedindetectionandsignaling
of increases in metabolites of muscle activity that occur as we
exercise ﬁrst to fatigue and then (if exercise is unabated) to
muscle pain.
In addition to their role in eﬀerent activity, both α-2
and β-2 adrenergic receptors have been implicated in animal
models of neuropathic and inﬂammation-induced pain [14–
17]. Rahman et al. [18] conclude that in healthy individuals,
a spinal pathway including α-2 receptor activity provides a
tonic inhibition of neuronal responses to mechanical pain,
and this inhibition is lost after peripheral nerve injury. In
regard to β-2 adrenergic receptor involvement, this may
diﬀer depending upon whether the chronic pain state is
new or well established. Coadministration into the temporo-
mandibular joint (TMJ) of the inﬂammatory agent, car-
rageenan,togetherwithaβ-2adrenergicreceptorantagonist,
prevents the chronic TMJ hyperalgesia that typically follows
carrageenan alone [17]. However, in established neuropathy
induced by sciatic nerve cuﬀ, chronic administration of β-
adrenergic receptor agonists reduce mechanical allodynia via
β-2 receptor activity [19].
Until recently, no solid candidates for the molecular
pathways signaling these sensations that we all have expe-
rienced have been conﬁrmed. A signiﬁcant breakthrough
occurred, however, when McCleskey and colleagues found
that ASIC3 receptors have the appropriate characteristics to
detect such ischemia; they are extraordinarily sensitive to
protons (acid), and they are expressed highly in dorsal root
ganglion (DRG) neurons that innervate skeletal muscle and
the myocardium [20, 21]. They noted that ASIC3 sensitivity
to acid is greatly enhanced if extracellular lactate and
adenosinetriphosphate(ATP)arealsopresent.Subsequently,
Sluka and colleagues conﬁrmed that ASIC3 is also impor-
tant in detecting hyperalgesia in skeletal muscle using a
model of chronic pain induced by inﬂammation. They also
demonstratedthatexercisingtheirmicetofatiguemadethese
animalsmorelikelytodevelophyperalgesiaafteracidicsaline
injections [22–24]. In related work, Hayes, Kaufman and
colleagues conﬁrmed in cat that ATP-sensitive P2X and ASIC
but not P2Y receptors on muscle aﬀerents are important in
pressor responses and changes in muscle blood ﬂow induced
by chemoreﬂexes similar to those occurring during muscle
activity [25, 26]. Extending this basic research on ASIC and
P2X receptors, Light and colleagues [27] recently showed
thatmouseDRGneuronsinnervatingmusclerespondpoorly
to a single metabolite like lactate, but respond much
better to physiological levels of combinations of the normalPain Research and Treatment 3
Table 1: Stress-related genes studied for DNA or mRNA eﬀects in FMS, CFS, or related disorders.
Adrenergic receptors α-1, α-2A, α-2C, β-1, β-2, β-3
Catechol-O-methyltransferase COMT
Cytokines IL6, IL10, LTa, CD14, TLR4
Dopamine receptors, enzyme, and transporter DRD1, DRD2, DRD3, DRD4, DBH,
SLC6A3
Glucocorticoid and mineralocorticoid receptors NR3C1, NR3C2
Ion channels Purinergic P2X4, P2X5, P2X7
Acid sensing ASIC1a, ASIC3
Transient vanilloid receptor TRPV1
Opioid receptors (kappa and delta) OPRK1, OPRD1
Serotonin receptors, synthesis gene and transporter HTR2a, HTR3a, HTR3b, TPH2, SLC6A4
metabolites of muscle work including acid, ATP, and lactate.
By applying speciﬁc antagonists for ASIC3, P2X, and TRPV1
receptors, Light et al. also conﬁrmed that these diﬀerent ion
channel receptors work together in concert to signal increases
in the levels of these metabolites. Furthermore, two types
of DRG neurons innervating muscle were seen: one that
responded to low metabolite levels (and may signal fatigue),
and another that responded maximally to higher metabolite
levels (and thus may signal muscle pain).
For the P2X receptors, in addition to their role as part
of a receptor complex detecting potentially painful levels
of metabolites, they also contribute to the establishment
of chronic pain state by inﬂuencing the function of spinal
microglia[28].Microgliabecomeactivatedundermanycon-
ditions, including trauma, inﬂammation, and infection, dur-
ing which they release chemical mediators including proin-
ﬂammatory cytokines. Following experimentally induced
inﬂammation, peripheral nerve injury or autoimmune mod-
els of neuritis, P2X4 expression is enhanced in activated
spinal microglia, and administration of P2X inhibitors leads
to a reduction in the hyperalgesia that otherwise follows
such injury [29–32]. This research on P2X4 involvement
in chronic pain conditions has been somewhat limited by
the lack of a speciﬁc P2X4 receptor antagonist and has
thus turned instead to mouse models where the P2X4 gene
has been disrupted. These P2X4 −/− mice show normal
responses to acute noxious stimuli, but reduced responses
to both chronic inﬂammatory pain induced by intraplantar
injection of Freund’s adjuvant and to neuropathic pain
induced by spinal nerve injury [29, 32]. Furthermore, fol-
lowing inﬂammatory treatments, P2X4-deﬁcient mice fail to
show the expected increase in prostaglandin E2, a potentially
important step in the initiation of inﬂammatory pain [31].
As noted by Light et al. [27], a third ion channel receptor
is part of the metabolite detecting complex, TRPV1, or
the capsaicin receptor. Fujii et al. [33] have reported that
inﬂammatory pain and delayed onset muscle soreness in
rats is blocked by both ASIC and TRP receptor antagonists.
Thus, upregulation of P2X4, ASIC3 and TRP receptors
in the DRG could contribute to exaggerated sensitivity to
metaboliteslinkedtofatigueandmusclepainsensations,and
upregulation of the same receptors on microglia could
play an important role in the establishment of chronic
pain following inﬂammation, nerve injury or autoimmune
conditions.
3. GeneticPolymorphisms Linkedto FMS
Susceptibilityor Subgroup Differences
Early research on genetic susceptibility in FMS focused on
serotonergicpathways.Therationaleforthisfocuswaspartly
that eﬀective and approved pharmacological treatments for
FMS included drugs commonly classiﬁed as serotonin and
norepinephrine reuptake inhibitors (SNRIs). Although a
few of the studies have been positive [34], the majority of
investigations on genes involving serotonin function have
not shown any association with FMS. For example, Frank
et al. [35] found no evidence of any diﬀerence in frequency
of polymorphisms involving the serotonin receptors 3A or
3B while Tander et al. [36] similarly saw no FMS diﬀerence
in serotonin receptor 2A polymorphisms, and G¨ ursoy [37]
found no links to serotonin transporter gene variants. In
the most recent investigation, reported by Nicholl et al. [38]
and Holliday et al. [39], two serotonergic gene SNPs for
serotonin receptor 2A and serotonin synthesis gene TPH2
were related to somatic symptoms in the general population
and in patients with chronic wide spread pain (CWP). There
wereofcourseverydiﬀerentclinicaldeﬁnitionsusedforFMS
in the negative studies versus CWP and somatic symptoms
in the latest positive studies, and none of these studies have
clearly deﬁned the characteristics of the subgroups where
the serotonin SNPs are seen. It was recently shown that
female patients with CFS only have increased serotonergic
tone (deﬁned by increased prolactin response to tryptophan
infusion) while those with CFS who have comorbid FMS
( C F S + F M S )h a v en o r m a ls e r o t o n e r g i ct o n eb yt h i st e s t[ 40];
note that this study used the older ACR criteria for FMS
including Tender Point exam. Thus, any future research on
serotonergic genes or other serotonin-related biomarkers in
FMS using the new broader deﬁnition for the disorder must
acknowledge the importance of subgrouping based on either
Tender Points or some other tests of hyperalgesic response.
Thesecondsystemtoreceiveintenseattentionforgenetic
polymorphisms was the other system directly altered by
SNRIs, the adrenergic nervous system. Here too outcomes4 Pain Research and Treatment
have generated mixed positive and negative ﬁndings [41],
w h i c hw eb e l i e v ea r el a r g e l yd u et od i ﬀerences in FMS sam-
ples, possibly involving whether the sample included larger
versus smaller percentages who had comorbid CFS. The
adrenergic gene that has received the most attention in FMS
to date is the val(158)met single nucleotide polymorphism
(SNP) for COMT, the primary enzyme that metabolizes
and inactivates catecholamines. G¨ ursoy et al. [42]r e p o r t e d
that speciﬁc polymorphisms for this COMT gene diﬀered in
frequency among FMS patients versus controls. They further
reportedthatthesepolymorphismswereunrelatedtoclinical
depression or other psychiatric disorders in their sample.
Cohen et al. [43] replicated this ﬁnding in a larger sample
of 209 female FMS patients compared to 152 of their own
nonaﬀected relatives, and they showed that the met allele
was linked to increased number of positive Tender Points.
More recently, Finan et al. [44] have linked speciﬁc COMT
haplotypes to catastrophizing, suggesting that this gene
inﬂuences cognitive coping strategies. Other studies have
shown that these as well as other gene haplotypes associated
with reduced COMT enzymatic activity are linked to greater
sensitivity to experimental pain among healthy women, and
greater risk of developing musculoskeletal disorders includ-
ing FMS and temporomandibular disorder (TMD) [45–
48]. In contrast, studies using patients having the broader
diagnosis of CWP with no attention to Tender Point have
generally not found any association with COMT haplotypes
evenwith very large samples [49, 50].This appears to suggest
that the characteristics of hyperalgesia and/or allodynia as
reﬂected by responses to Tender Point testing and to experi-
mental pain tasks may be importantly related to the COMT
haplotypesandtheirlinkstodevelopmentofTMDandFMS.
Further large-scale prospective longitudinal research on the
role of COMT-related genes in the pathogenesis of TMD and
FMS is in progress, and will provide more deﬁnitive tests of
the role of these genes.
Additional research on adrenergic genes has indicated
that haplotypes inﬂuencing α-1a adrenergic receptor and the
β-2 adrenergic receptor diﬀer in patients with FMS. Vargas-
Alarc´ on et al. [51] examined SNPs for α-1, β-2, and β-3
receptors in samples of Spanish and Mexican FMS patients
versus controls. Of these, only the β-2 adrenergic receptor
SNPs were diﬀerentially expressed in the FMS patients from
both locations while in the Spanish patients only, there was
also increased frequency of one of the 3 α-1 adrenergic
receptor SNPs studied. In a prospective study, Herlyn et al.
[52] reported an association of the same α-1 receptor poly-
morphism, the rs1048101, with increased risk of develop-
ment of complex regional pain syndrome following fracture
of the radius. Polymorphisms for the adrenergic receptors α-
2A and α-2C have both been linked to IBS and to broader
somatic complaints including pain in these patients [53].
Xiao et al. [54] found that the Gly16Arg polymorphism
for the β-2 adrenergic receptor was less frequent in FMS
than controls. Those FM patients carrying the alternative
Arg16Arg polymorphism showed lower intracellular cyclic
AMP functioning. It is important to note that Nackley
et al. [47] found that β-2 adrenergic receptors are involved in
the increase in pain sensitivity that results from diminished
COMT activity. Thus, it is possible that the combined
presence of genes that downregulate both β-2 receptors and
COMT activity in the same individual may more greatly
enhance pain sensitivity and risk for FMS than either
gene polymorphism individually. Our research group [55]
demonstratedshort-termreductioninclinicalpainratingsin
patients with FMS (including 40% with comorbid CFS) and
TMD following β-receptor blockade with low-dose propra-
nolol (which blocks both β-1 and β-2 receptors). Subse-
quently, Tchivileva et al. [56] used a double-blind crossover
design to compare one week of propranolol versus placebo
treatment, and similarly found that total pain ratings of
TMDpatientsweredecreasedbytheβ-adrenergicantagonist;
they also found that propranolol did not alter sensitivity to
experimental pain in all TMD patients, but did reduce it in
those with the COMT haplotype linked to decreased enzyme
production.
Altogether, these ﬁndings indicate that genetic haplo-
types for α and β-adrenergic receptors and COMT confer an
inherent susceptibility and are related to risk of developing
chronic musculoskeletal and gastrointestinal pain disorders
including FMS, TMD, and IBS. Future FMS research should
include larger and better characterized samples so that it
can be determined whether these risks diﬀer depending on
the presence or absence of comorbid CFS, IBS, orthostatic
intolerance, and other clinical factors linked to altered au-
tonomic/adrenergic function.
Anothercentralpathwaythathasreceivedsomeattention
among genetic studies in FMS and related disorders is the
dopaminergic pathway. Zubieta et al. [57] reported that the
SNPs linked to reduced COMT activity were associated with
changesineﬀectsofmu-opioidtransmittersonexperimental
pain. Wood et al. [58] had observed that FMS patients show
abnormal dopamine responses to pain. Although Triester et
al. [59] found that healthy subjects with speciﬁc SNPs for
the dopamine transporter gene were less tolerant to noxious
cold, Ablin et al. [60] found no evidence for diﬀerences
amongIsraeliFMSpatientsinhaplotypesforthedopaminer-
gictransportergeneorforthesubstancePreceptor.However,
genetic variants of the dopamine receptor-4 (DRD4) have
been associated with FMS or with an overlapping disor-
der, migraine headaches, in several studies [61–63]. Other
dopamine receptor and transporter gene SNPs were not
linkedtomigraineinSpanishsamples[64,65]butdopamine
transporter and dopamine beta-hydroxylase gene SNPs did
show an association to migraine with aura in other European
samples [66].
The purinergic receptors are another broadly inﬂuential
pathway deserving of attention in genetic studies of FMS
and other disorders involving chronic pain and fatigue. IFN-
gamma has been shown to upregulate P2X4 receptors (both
expression and protein) in vascular endothelial cells [67].
Furthermore, ﬂow-mediated dilation is impaired in P2X4
knockout mice, which have higher BP and have altered nitric
oxide (NO) function, even excreting less NO in urine [68].
In one study, a polymorphism linked to lower expression of
the P2X7 receptor was associated with subgroups of patients,
with both systemic lupus erythematosus and rheumatoid
arthritis having poor apoptotic function [69]. Also, SNPsPain Research and Treatment 5
for the P2X7 receptor gene have been associated with
clinical anxiety and both monopolar and bipolar depression
disorders [70–73]. Yet to date, there have been no published
studies of which we are aware examining genetic variants
of any purinergic receptor genes in FMS, CWP, CFS, IBS,
migraine, or any other overlapping multisymptom disorder.
4. GeneExpressionResearch
Gene expression as opposed to genetic SNPs (mRNA
rather than DNA) is typically determined through one of
two major methods: microarray where the full genome
is assessed together, and quantitative real-time polymerase
chain reaction (qPCR) where selected primers for speciﬁc
genes are examined individually. The micro-array approach
isattractiveformultisymptomdisorderslikeFMSwheredys-
regulation in many physiological systems may potentially be
involved,simplybecauseallofthemcanbeexaminedatonce.
TheprimarydrawbacktomicroarrayforFMSresearch,how-
ever, is that due to examining such a huge number of out-
come measures in the same study, it is necessary to use a very
large patient and control sample and/or to lump together
multiple genes to assess as a single pathway, in order to
control for a tremendous statistical problem of false-positive
ﬁndings. Some authors ignore the false positive problem,
and report each gene as though it were an independent test;
for example, Gow et al. [74] studied only 8 CFS patients
versus 7 controls using the full 33,000 gene sequences from
the Aﬀymetrix array, and report that these groups diﬀer
signiﬁcantly in 366 genes (roughly 1% of genes tested). This
is very likely one of the factors that has led to frequent
nonreplication of results. In contrast, the number of genes
examined using qPCR is usually 1–40, and they are typically
selected on the basis of representing a speciﬁc pathway where
prior research has indicated a functional diﬀerence. Several
studies have reported that from 1–6 genes related to immune
function were upregulated in leukocytes of CFS patients
compared to controls [75–78]. One option, employed by
Kerr and colleagues to examine patients with CFS, is to use
microarray for an initial study to identify pathways where
multiple gene show diﬀerential expression, and then follow
this with qPCR on the strongest candidate genes within
those pathways [79, 80]. However, Frampton and colleagues
[81] have recently found that even using a 44-gene proﬁle
generated from their original research, its utility in prospec-
tively distinguishing CFS patients from controls in a new test
was only fair (correctly identifying only about 60% of those
tested).
One important advantage for gene expression protocols
is that one can examine the mRNA levels before and after
a challenge. Many genes are upregulated or downregulated
quite rapidly in response to normal physiological events,
like physical exercise, pain, emotional stress, exposure to an
infectious agent, toxins, and many others. In this way, the
dysregulation that may be too subtle for detection in the
resting state can be revealed. In an early investigation using
micro-array to examine gene expression changes in response
to an exercise challenge, the Centers for Disease Control
(CDC) research group elected to use a moderate bicycle
exercise task (using 70% percent of age-predicted maximum
heart rate) rather than a maximal exercise task, which has
longbeenthepreferredoptionforexercisescientistsfocusing
on the cardiovascular system [82]. Their rationale for this
decision, which is compelling, was that a submaximal exer-
cise task has 3 key advantages over a maximal exercise test.
First, even debilitated patients can complete moderate exer-
cise on a stationary bicycle. Second, it can be performed for
an extended period of time (here, 20min) and duration can
be matched across subjects while maximal tests are briefer
(7–12min) and the duration for deconditioned CFS patients
may average only 60–75% of that in controls, which could
by itself contribute to gene expression diﬀerences. Third, this
type of exercise is more typical of the activities of daily living
that cause postexertional malaise (deﬁned as worsening
fatigue, pain, or feelings of sickness), a key symptom of
CFS. This CDC-based study observed increased expression
of genes in a number of pathways at 24 hours after the
exercise in the 5 CFS versus 5 controls, of which the most
relevant were ion transport and ion channel activity genes.
A more recent case-control study with another small sample
(8 CFS patients versus 7 controls) using the same exercise
p r o t o c o lb u tw i t hq P C Ra s s a y sf o rm R N Aa t6h o u r sa f t e r
the exercise showed increased activity in a pathway linked
to complement activation [83]. Using a diﬀerent Bayesian
approachtoanalyzethesamedataset,whichlookedforgenes
thatdiﬀeredatbaselineaswellasinresponsetothechallenge,
Lin and Hsu [84, 85] found diﬀerences in the glucocorticoid
receptor gene NR3C1. It should be noted that both Goertzel
et al. [85] and Rajeevan et al. [86]h a dp r e v i o u s l yr e p o r t e d
that NR3C1 haplotypes were diﬀerentially present in CFS
patients while Macedo et al. [87] observed that a related
gene SNP for NR3C2, the mineralocorticoid receptor, was
diﬀerentially present in FMS patients and this was linked to
lower baseline gene expression of both NR3C1 and NR3C2.
To date, the only research examining leukocyte gene
expressionresponsesafterexerciseinpatientswithFMS-only
and patients with CFS plus comorbid FMS has been by our
University of Utah research team [88–90]. The 1994 Fukuda
et al. criteria plus the Reeves criteria [9]w e r eu s e dt od e ﬁ n e
CFS, including persistent or relapsing fatigue of 6 months
duration or longer that results in substantial restriction of
life activities, and is accompanied by at least 4 of these 8
additional symptoms: unusual worsening of fatigue, pain, or
general unwellness following exertion, impaired memory or
concentration, muscle pain, joint pain, unrefreshing sleep,
change in headaches, sore throat, and tender lymph nodes.
To deﬁne FMS, patients had to have widespread mus-
cle/connective tissue pain, including all 4 body quadrants
(bilateral, upper, and lower body) for 3 months or longer,
and hyperalgesic responses to pressure at Tender Points
(with pain reported for at least 11 of 18 Tender Points)
[91]; activity-restricting fatigue was not involved in the
deﬁnition of FMS, and the FMS-only group reported only
milder fatigue that rarely limited life activities. We modeled
our 25-minute moderate exercise stressor after the one used
by the CDC research, but extended the blood sampling
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corresponding with the typical duration of after the exer-
tional malaise reported by many CFS patients. In our recent
investigation, [89], we have also employed a much larger
sample including 48 patients with CFS only or CFS with
comorbid FMS, and 18 patients with FMS only who report
some daily mental or physical fatigue but do not meet
criteria for CFS. As our primary comparison group, we
tested 49 healthy controls who were age-matched to the CFS
and CFS+FMS patients. Because of the risks and problems
associated with asking patients to be withdrawn from
antidepressant medications, 30 of 48 CFS patients (63%)
and 13 of the 18 FM-only patients (72%) were tested while
continuing their usual antidepressants; however, to mitigate
possible confounding eﬀects of these medications, 11 of 49
control subjects (23%) also had been diagnosed and were
currently on medication for clinical depression. We also
included another deconditioned patient group, 20 multiple
sclerosis (MS) patients who reported daily fatigue that
signiﬁcantly impacted functioning [90]. The genes selected
for qPCR assay included adrenergic receptors and COMT,
sensory ion channel receptors P2X4, P2X5, ASIC3, and
TRPV1, and several cytokine and immune genes including
IL10, IL6, lymphotoxin-α (LTa), Toll-like receptor-4 (TLR4),
and cluster of diﬀerentiation-14 (CD14). At baseline, there
were no diﬀerences in gene expression between any of the
CFS groups or the MS group versus the controls. As depicted
in Figure 1, healthy controls (including those on medication
for clinical depression) showed no signiﬁcant increases after
moderate exercise in any of the genes under study, despite a
trend based on some healthy subjects showing an increase in
β-1 adrenergic receptor expression. In contrast, the majority
of patients with CFS only or CFS+FMS showed postexercise
increases in most of the sensory ion channel genes and
all of the adrenergic receptor and COMT genes, as well
as IL10, diﬀering from controls in all of these responses.
Importantly, patients with CFS only and CFS+FMS showed
nearly identical increases in all genes except ASIC3, which
increased only in the CFS+FMS group. These postexercise
increases were evident as rapidly as half an hour after the
moderate exercise task, and persisted for the full 48 hours.
These diﬀerences from controls were also evident when
comparisons involved reduced samples matched for actual
work performed to attain 70% of their predicted maximum
heart rate, thereby controlling for diﬀerences in ﬁtness level
[89]. Postexercise severity of clinical pain and fatigue ratings
in CFS-only and CFS+FMS patients were correlated with
increases in gene expression, especially with P2X4, α-2A and
β-2 receptors (r = +0.43, +0.48, and +0.44 for pain, and
r = +0.51,+0.60,and+0.47forfatigue,resp.; P < 0.01)[89].
Unlike those with CFS+FMS, patients with FMS only
showed no signiﬁcant increases in any gene after moderate
exercise (see Figure 2). The other patient group, the MS
patients, showed modest and transitory increases in α-2A
and β-1 adrenergic receptors, but these were signiﬁcantly
lower overall than the increases in the CFS groups, and they
had no increases in any of the sensory ion channel genes.
The MS group responses were in fact very similar to 10
healthycontrolswhoexercisedfor25minutesatmuchhigher
intensity, 85% of their age-predicted maximum heart rate,
who likewise increased β-1 adrenergic receptor expression,
but not any sensory receptor. The very modest responses of
this high-intensity control group contradict the possibility
that, although our moderate exercise task was individually
adjusted to evoke a similar cardiovascular response, it was
still a more intense stressor for the CFS patients and this
resulted in their greater gene expression changes.
Increases in P2X4, P2X5, TRPV1, and ASIC3 plus
exaggerated COMT, α-2A, and β-2 adrenergic receptor
expression following moderate exercise have been a unique
proﬁle in CFS and CFS+FMS patients, not evident in any
other patient group with chronic fatigue or pain that we
have examined to date. Both the adrenergic receptor and ion
channel gene expression was directly correlated with the
severity of postexertional fatigue and pain reported by the
CFS group. It is notable that our gene expression responses
did identify a subgroup among the CFS patients showing
decreases rather than increases in α-2A adrenergic receptors
lasting for 48 hours; this subgroup did not show increases
in any other genes, and they were much more likely to
have a clinical history of orthostatic intolerance than other
CFS patients. These clinical and gene expression diﬀerences
provide a helpful starting point for individualized treatment
options. Surprisingly, despite their shared ﬁbromyalgia and
the fact that both groups reported postexercise increases
in pain and fatigue, the FMS-only group was unlike the
CFS+FMS group and showed no postexercise increases in
these genes.
However, the FMS-only patients did show evidence of
dysregulation in the sensory ion channel pathway at baseline
prior to exercise. These patients showed increased expression
of both P2X4 and TRPV1 receptors at baseline, along with
increased IL10 [89]. It is possible that these patients diﬀered
from the CFS+FMS primarily in their ability to cope with
theirsensationsoffatigue.Ifso,theywouldreportlessfatigue
severity as a chronic symptom, and be able to remain more
activeindailylifeactivities.Eventhoughallpatientsandcon-
trols were instructed to refrain from formal exercise beyond
slow walking for 48 hour before and 48 hours after our
exercisetest,theFMS-onlypatientsmayhavebeenfunctional
enough to have baseline responses that were nevertheless
elevated by more activity while the CFS+FMS and CFS-only
groups did not. This possibility might be best addressed in
future research by use of activity logs and objective doc-
umentation such as with the Actigraph monitoring systems.
We have interpreted these observations as indications
of dysregulation in the primary metabolite-detecting neural
pathway that senses products of muscle activity including
protons, lactate, and ATP. Large-scale increases in P2X4,
P2X5, TRPV1, and ASIC3 receptors in the DRG would
potentially increase sensitivity to even low levels of these
metabolites suchthat even activity asmild as upright posture
and slow walking in CFS or CFS+FMS patients could pro-
duce sensations of fatigue and muscle pain that normal
individualswouldonlyfeelduringextremeactivity[92].One
major problem with this research is that directional changes
in gene expression are tissue speciﬁc, and it is not possible to
obtain samples of DRG or other neural tissues from living
human individuals without causing irreversible damage.Pain Research and Treatment 7
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Figure 1: Increases in leukocyte gene expression at 30 minutes, 8 hours, 24 hours, and 48 hours after moderate intensity exercise in healthy
controls (top), CFS+FMS patients (middle), and CFS-only patients( b o t t o m ) .D a t af o re a c hg e n e( s e ec o l o rc o d e s )a r ed e p i c t e da sf o l d
increases from preexercise baseline at each of the 4 sampling times; thus, 2.0 = twice as much expression as at baseline, and so forth.
CFS+FMS and CFS only signiﬁcantly greater than controls for P2X4, P2X5, TRPV1, α-2A, β-1, β-2 adrenergic receptors, COMT, and IL10
assessed as area under the curve across all 4 postexercise sampling times (P < 0.05). CFS+FMS greater than CFS-only and controls for ASIC3
(P < 0.05). Data are adapted from results reported by Light et al. [89].
Leukocytes, in contrast, are easily obtained without risk on a
repeated basis, but we are compelled to use them as indirect
markers of these critical neural cells. To reinforce our inter-
pretation, we must depend on research in animal models
where the hypothesized parallel changes in leukocyte and
DRG genes can be directly conﬁrmed or refuted. A recently
emerging literature, however, supports the use of gene
expression proﬁles from leukocytes as useful surrogates to8 Pain Research and Treatment
All controls at times indicated after moderate exercise
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Figure 2: Increases in leukocyte gene expression at 30 minutes, 8 hours, 24 hours, and 48 hours after moderate intensity exercise in healthy
controls (top), FMS only patients (upper middle), multiple sclerosis patients (lower middle), and after higher intensity exercise in healthy
controls (bottom). FMS-only do not diﬀer from moderate exercise controls in any gene. MS patients signiﬁcantly greater than moderate
exercise controls for α-2A, β-1 and β-2 adrenergic receptors (P < 0.05). High-intensity controls signiﬁcantly greater than moderate intensity
controls for adrenergic receptors, LTα and IL10 (P < 0.05) but not for any sensory gene. CFS+FMS combined with CFS-only patients from
Figure 1 signiﬁcantly greater than high intensity controls for ASIC3, P2X4, TRPV1, α-2A and β-2 adrenergic receptors, and COMT (P <
0.05). Data are adapted from Light et al. [89], White et al. [90], and unpublished observations.Pain Research and Treatment 9
neuronal expression for genes linked to pain aﬀect and
mood [93–95], thus strengthening use of this approach in
the context of FMS. In all studies of gene expression, there
is also the additional limitation that this is an indication
that processes have been engaged in an eﬀort to increase or
decrease the production of a speciﬁc receptor or other pro-
tein, and that changes in actual protein levels may not always
occur.
5. MethodologicalIssuesforFutureResearchon
Genetics andGene Expressionof FMS
One of the diﬃcult issues for this area of research is that
many patients with FMS, CFS, and related multisymptom
disorders develop clinical depression secondary to their
chronic disabling pain and fatigue symptoms, which make
performing the usual activities of work and family life
diﬃcult or even impossible. When attempting to separate
biological eﬀects of depression from the eﬀects of their
primary disorder, some investigations have elected to study
only those FMS patients who do not meet criteria for clinical
depression [40, 55]. This strategy is vulnerable to the criti-
cism that by eliminating FMS patients with depression, the
sample may be biased and nonrepresentative, and especially
mayincludeonlylessseverelyaﬀectedFMSpatients.Another
approachwhichmaybemoreexpensiveintermsofresources
but more valid is to include patients with clinical depression
who do not meet criteria for FMS, CFS, or any other multi-
symptom disorderasasecondcomparisongroup,alongwith
healthy controls. This latter approach could be especially
usefulwhenattemptingtomatchthepatientandcomparison
groups for a number of other characteristics, including
current or prior use of certain medications, aﬀective state,
anduseversusavoidanceoftraditionalmedicaltreatmentfor
chronic conditions. Using patients with clinical depression
who do not meet criteria for FMS as a comparison group
is also extremely important because of the hypothesis that
CFS and FMS may be severe somatization variants of major
depressive disorder, a possibility which many CFS and FMS
patientsdispute[96,97].Adiﬀerentconcernappliestoinves-
tigations in which the FMS patients are required to stop all
theirmedicationsforanextendedperiodoftime,becausethe
more severely aﬀected patients may be unwilling or unable
to do this. However, if all FMS patients are tested while using
a speciﬁc medication and none of the controls are tested on
this medication, gene expression diﬀerences between groups
could be due to the medication and not the diagnosis.
For example, Salemi et al. [98] found that both kappa-
and delta-opioid receptor genes had higher expression in
skin of patients with FMS versus healthy controls. However,
because the report does not clarify medication use or recent
cessation, the diﬀerences could also be due to more FMS
patientseithercurrentlyusingopioid medications or,equally
problematic,havingreceptorsthatareina“withdrawalstate”
due to stopping these medications for only a few days prior
to the study. In contrast, one of the better designed studies to
date by Macedo et al. [87] reported reduced leukocyte gene
expression of both the glucocorticoid receptor NR3C1 and
the mineralocorticoid receptor NR3C2 in patients with FMS,
all of whom stopped their antidepressants for at least 2 weeks
prior to testing. This study was also especially well designed
in that they concurrently tested the functionality of the
corticosteroid pathway by measuring basal serum and saliva
cortisol levels and examining responses to dexamethasone.
Finally, they looked for genetic polymorphisms for these
receptors, and found an excess of one allele for the miner-
alocorticoid receptor, which was then linked to diminished
expression of both these related genes NR3C2 and NR3C1.
In our research on gene expression diﬀerences in patients
with FMS (including 72% tested on SSRI or SNRI antide-
pressants), we have recently compared this group to patients
with moderate to severe clinical depression persisting despite
SSRI and SNRI treatment as well as to healthy individuals
including a subgroup with milder depression that was well
controlled by antidepressants (Light et al., unpublished
observations). We observed that the FMS and the treatment-
refractory depressed patients diﬀered from the controls in
expression of a number of the same genes, including similar
increased expression of the ASIC1a gene. In mice, genetically
disrupting ASIC1a or administering an ASIC1a antagonist
reduced depressive-like behaviors in the forced swim test
while restoring ASIC1a to the amygdala with a viral vector
reversed this eﬀect [99]. In our FMS and depressed patients,
this similar increase in ASIC1a expression may reﬂect com-
mon neural dysregulation that contributes to both of these
disorders, or instead may reﬂect the consequences of per-
sisting depressive symptoms. Importantly, the eﬀects do not
appear linked to antidepressant use, since this factor was not
reliably related to ASIC1a expression in any of our statistical
models.
One weakness of the exemplary study by Macedo et al.
[87] was a failure to examine their patients for clinical infor-
mation that might more closely identify the speciﬁc clinical
characteristics of the FMS who showed this genetic and
genomic proﬁle; speciﬁcally, it would have been very desir-
able to know whether they also met criteria for comorbid
CFSorotheroverlappingdisorders.Wefeelverystronglythat
in a heterogeneous syndromic disorder like FMS, research
is greatly strengthened when meaningful subgroups can be
diﬀerentiated. The ﬁndings can then be more speciﬁcally
useful for clarifying factors linked to pathogenesis and prog-
nosis. The well-deﬁned subgroups together with the genetic
and genomic data, when combined, can also provide a
clear rationale for individualized physiological targets for
treatment.
To date, most of the research summarized above has
taken a single blood sample from patients and controls, and
examined gene SNPS (DNA) or gene expression (mRNA).
Gene expression responses to exercise have rarely been em-
ployed,andgeneexpressionresponseshavenotbeenassessed
to any other types of challenge. Future research should
continue to examine gene expression responses to exercise
and other physical challenges, including pain stimuli and
psychological stressors which have particular relevance in
hypotheses about FMS onset and progression. When exercise
is used as the challenge, it is important to consider both
submaximal and maximal exercise tasks as valid options,10 Pain Research and Treatment
depending upon the speciﬁc goals of the study. We reiterate
that submaximal exercise is closer to the usual physical
activity of daily life that leads to worsening of muscle pain
and fatigue for 24–48 hours in patients but not healthy
individuals, and thus may be better than maximal exercise
at revealing physiological pathways that are dysregulated in
patients versus controls. If possible, longitudinal research
shouldbeencouragedinwhichbothgeneticandgeneexpres-
sion measures are obtained in subjects who are still healthy
buthavegeneticSNPspreviouslylinkedtoFMSsusceptibility
(for NR3C2, serotonin, COMT, or other haplotypes), and
gene expression responses reexamined after a period of years
when a subgroup of these individuals may meet criteria for
FMS.
As a ﬁnal point of emphasis, there is a critical need to
continue to integrate genetic and genomic clinical research
with closely associated research in animal models of FMS—
what has been called “reverse translational research.” At
this time, for example, research with animal models is
critical in the development and testing of new receptor
antagonists, such as a speciﬁc antagonist for P2X4 receptors.
This type of pharmacological tool could be important both
for its research and therapeutic possibilities in FMS. Genetic
mutantandknockoutmousemodelsarealsoextremelyvalu-
able to help elucidate multiple physiological pathways that
are inﬂuenced by any genetic or genomic variations of inter-
est.Asstatedpreviously,virtuallyallgeneexpressionresearch
in humans is based onleukocytes, and must acknowledge the
limitation that this may or may not parallel gene expression
changes in other organs and tissues, like the DRG, spinal
cord, or speciﬁc brain regions of interest. Parallel studies
in animal models can explore gene expression changes in
neural tissues and thus greatly reinforce the clinical ﬁndings.
Thus, much more translational clinical research and reverse
translational basic research on adrenergic and purinergic
genes and gene expression is encouraged for expanding
our understanding of the physiological and environmental
factors that initiate and maintain the chronic symptoms
of FMS, and to lay the foundation for treatments that are
more eﬀective and have fewer side eﬀects for each individual
patient.
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